Off-Label Use of Upadacitinib in Crohn's Disease: A Case Series

被引：0

|

作者：

Choudry, Nida ^{[1
]}

Forster, Erin ^{[1
]}

Kessler, Ethan ^{[1
]}

机构：

[1] Med Univ South Carolina, Charleston, SC USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 12S期

关键词：

D O I：

10.14309/01.ajg.0000995964.25499.a5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S55

引用

收藏

页码：S15 / S15

页数：1

相关论文

共 50 条

[41] FavipiravirNephrotoxicity following off-label use: case report
Reactions Weekly, 2022, 1929 (1) : 283 - 283
[42] BevacizumabRetinal breaks and off-label use: case report
Reactions Weekly, 2022, 1924 (1) : 120 - 120
[43] NivolumabFever following off-label use: case report
Reactions Weekly, 2016, 1601 (1) : 186 - 186
[44] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[45] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[46] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[47] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[48] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[49] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[50] Paclitaxel/vemurafenibMyelosuppression and off-label use: case report
Reactions Weekly, 2022, 1888 (1) : 292 - 292

← 1 2 3 4 5 →